Fidelity Investments
MPLT

Fidelity Investments’s MapLight Therapeutics MPLT Stock Holding History

Fidelity Investments’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.5M Buy
823,556
+619,055
+303% +$17.8M ﹤0.01% 1724
2026
Q1 		$4.16M Buy
204,501
+203,597
+22,522% +$3.64M ﹤0.01% 2362
2025
Q4 		$15.9K Buy
+904
New +$15.1K ﹤0.01% 4566

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments's MPLT Position: Q2 2026 in Review

Fidelity Investments increased its MapLight Therapeutics (MPLT) stake by 303% in Q2 2026, buying an estimated $17.8M and bringing the position to 823,556 shares worth $29.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1724.

Fidelity Investments first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 106 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Fidelity Investments held 823,556 shares of MapLight Therapeutics worth $29.5M as of Q2 2026.
  • Fidelity Investments bought 619,055 MapLight Therapeutics shares in Q2 2026, an estimated $17.8M.
  • MapLight Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1724 holding.
  • Fidelity Investments first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 106 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.